Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective.

Matsela, Lineo Marie; Cleary, Susan; Wilkinson, Thomas

Matsela, Lineo Marie; Cleary, Susan; Wilkinson, Thomas.

Afiliação

Matsela LM; Health Economics Division, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. mariematsela@gmail.com.
Cleary S; Health Economics Division, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Wilkinson T; Health Economics Division, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Cost Eff Resour Alloc ; 20(1): 69, 2022 Dec 12.

Article em En | MEDLINE | ID: mdl-36510230

Palavras-chave

Bortezomib; Cost effectiveness; Lenalidomide; Relapsed/refractory multiple myeloma; Second-line treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2022 Tipo de documento: Article